Vivesto AB (VIVE) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.039x

Based on the latest financial reports, Vivesto AB (VIVE) has a cash flow conversion efficiency ratio of -0.039x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.46 Million ≈ $-695.20K USD) by net assets (Skr166.56 Million ≈ $17.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Vivesto AB to measure how much of total assets are equity-financed.

Vivesto AB - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Vivesto AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VIVE cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Vivesto AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vivesto AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Talisman Mining Ltd
AU:TLM
-0.083x
West International AB
ST:WPAY
0.282x
Caring Brands, Inc. Common Stock
NASDAQ:CABR
0.275x
Art Nirman Limited
NSE:ARTNIRMAN
0.004x
SRJ Technologies Group Plc
AU:SRJ
-0.052x
Solo Brands, Inc.
NYSE:SBDS
-0.347x
J D Wetherspoon PLC
LSE:JDW
0.175x
SACCHERIA F.LLI FRANCES.
F:YV1
N/A

Annual Cash Flow Conversion Efficiency for Vivesto AB (2004–2025)

The table below shows the annual cash flow conversion efficiency of Vivesto AB from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Vivesto AB stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr124.58 Million
≈ $13.41 Million
Skr-33.96 Million
≈ $-3.65 Million
-0.273x +8.64%
2024-12-31 Skr158.33 Million
≈ $17.04 Million
Skr-47.25 Million
≈ $-5.08 Million
-0.298x +14.14%
2023-12-31 Skr197.80 Million
≈ $21.29 Million
Skr-68.74 Million
≈ $-7.40 Million
-0.348x -40.46%
2022-12-31 Skr325.42 Million
≈ $35.02 Million
Skr-80.52 Million
≈ $-8.66 Million
-0.247x +6.56%
2021-12-31 Skr549.71 Million
≈ $59.16 Million
Skr-145.56 Million
≈ $-15.67 Million
-0.265x +11.23%
2020-12-31 Skr686.74 Million
≈ $73.90 Million
Skr-204.86 Million
≈ $-22.05 Million
-0.298x -3460.04%
2019-12-31 Skr819.39 Million
≈ $88.18 Million
Skr-6.87 Million
≈ $-738.89K
-0.008x +97.01%
2018-12-31 Skr424.05 Million
≈ $45.63 Million
Skr-118.84 Million
≈ $-12.79 Million
-0.280x +21.79%
2017-12-31 Skr345.04 Million
≈ $37.13 Million
Skr-123.63 Million
≈ $-13.30 Million
-0.358x +19.08%
2016-12-31 Skr300.37 Million
≈ $32.32 Million
Skr-133.01 Million
≈ $-14.31 Million
-0.443x -12.69%
2015-12-31 Skr326.05 Million
≈ $35.09 Million
Skr-128.13 Million
≈ $-13.79 Million
-0.393x -37.13%
2014-12-31 Skr375.71 Million
≈ $40.43 Million
Skr-107.67 Million
≈ $-11.59 Million
-0.287x +7.04%
2013-12-31 Skr281.91 Million
≈ $30.34 Million
Skr-86.90 Million
≈ $-9.35 Million
-0.308x -41.47%
2012-12-31 Skr319.15 Million
≈ $34.35 Million
Skr-69.54 Million
≈ $-7.48 Million
-0.218x -13.63%
2011-12-31 Skr273.47 Million
≈ $29.43 Million
Skr-52.44 Million
≈ $-5.64 Million
-0.192x +2.07%
2010-12-31 Skr294.17 Million
≈ $31.66 Million
Skr-57.60 Million
≈ $-6.20 Million
-0.196x -147.13%
2009-12-31 Skr141.80 Million
≈ $15.26 Million
Skr-11.23 Million
≈ $-1.21 Million
-0.079x -133.97%
2008-12-31 Skr61.21 Million
≈ $6.59 Million
Skr14.28 Million
≈ $1.54 Million
0.233x +167864.83%
2007-12-31 Skr64.81 Million
≈ $6.97 Million
Skr9.00K
≈ $968.54
0.000x +100.07%
2006-12-31 Skr110.30 Million
≈ $11.87 Million
Skr-22.73 Million
≈ $-2.45 Million
-0.206x -7.71%
2005-12-31 Skr58.90 Million
≈ $6.34 Million
Skr-11.27 Million
≈ $-1.21 Million
-0.191x -192.02%
2004-12-31 Skr31.40 Million
≈ $3.38 Million
Skr6.53 Million
≈ $702.68K
0.208x --

About Vivesto AB

ST:VIVE Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$9.98 Million
Skr92.78 Million SEK
Market Cap Rank
#27017 Global
#587 in Sweden
Share Price
Skr8.38
Change (1 day)
-3.12%
52-Week Range
Skr0.08 - Skr17.00
All Time High
Skr17.00
About

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more